Zhonghui Biology (中慧生物) is a Chinese brand name for which no verifiable commercial evidence was supplied in this batch.
Last updated October 31, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
The supplied evidence does not contain any information about 中慧生物. The two snippets provided are Sina Finance pages: one is a news article about XPENG's announcement of its "XPENG AI ENGINEERING" intelligent-vehicle solutions business at the 2026 Paris Motor Show, and the other is a Sina Finance market-quote page for the Shanghai Composite Index (000001.SH). Neither mentions 中慧生物, a company of that name, its products, ownership, or history. Because no official-site, Wikipedia, or news evidence about this subject was supplied, this dossier cannot responsibly describe the brand's identity, offerings, industry, headquarters, founders, or market position. The name suggests a Chinese life-sciences or biotechnology concern, but that is an inference from the name alone and is not evidence; it must not be treated as a factual claim. This entry is therefore flagged for review. It should be re-enriched once verifiable sources — such as the company's official website, a stock-exchange filing, a regulatory registration, or reputable press coverage — are attached to the record.
Controversies
2026
Zhonghui Bio (中慧生物) announces resignation of non-executive director Yu Jianlin
Zhonghui Bio (中慧生物), whose shares have been suspended from trading since April 1, 2026 pending publication of its 2025 annual results, announced on the evening of October 12, 2026 that non-executive director Yu Jianlin had resigned due to personal work adjustments. He is the second director to leave recently, following CFO Li Runxiang's September resignation; the annual report remains unpublished because audit procedures on certain fund investments and consulting payments and a related internal inquiry by the board audit committee are incomplete and pending further investigation.
Recent events
Zhonghui Bio (中慧生物) announces resignation of non-executive director Yu Jianlin[3]
Zhonghui Bio (中慧生物), whose shares have been suspended from trading since April 1, 2026 pending publication of its 2025 annual results, announced on the evening of October 12, 2026 that non-executive director Yu Jianlin had resigned due to personal work adjustments. He is the second director to leave recently, following CFO Li Runxiang's September resignation; the annual report remains unpublished because audit procedures on certain fund investments and consulting payments and a related internal inquiry by the board audit committee are incomplete and pending further investigation.
Sources3 sources
Cite this profile: Cite the canonical profile. /brand-wiki/中慧生物 · Editorial policy · How profiles are compiled